Celgene Corp (CELG) 135.78 $CELG
Biotech NantKwest Stock Surges On 1st Day Of Trading
at Investor's Business Daily - 1 hr 46 mins ago
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 72.33 (+3.47), NK: 33.89 (+33.89), ALXN: 202.89 (+4.79), RCPT: 227.79 (+0.70), AMGN: 173.17 (+7.63), JUNO: 48.97 (+1.17), CELG: 135.78 (+3.22)
Celgene (CELG) Crosses Pivot Point Resistance at $133.64
Comtex SmarTrend(R) - Tue Jul 28, 9:35AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $132.37 today and has reached the first level of resistance at $133.64. Investors may be interested in a cross of the next upside pivot targets of $134.71 and $137.05.
CELG: 135.78 (+3.22)
Celgene Corporation Commences Tender Offer for Receptos, Inc.
Business Wire - Tue Jul 28, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
RCPT: 227.79 (+0.70), CELG: 135.78 (+3.22), CELGZ: 2.03 (+0.03)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 315.88 (+6.45), GILD: 113.03 (+2.49), CELG: 135.78 (+3.22)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.73%
Comtex SmarTrend(R) - Mon Jul 27, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 135.78 (+3.22)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.73% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 135.78 (+3.22)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 315.88 (+6.45), GRUB: 32.39 (+1.38), XBI: 259.14 (+7.36), IBB: 382.50 (+8.92), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.34 (-0.15), BIIB: 315.88 (+6.45), LGND: 106.54 (+3.99), AMGN: 173.17 (+7.63), REGN: 557.06 (+17.03), EXEL: 5.54 (+0.10), CELG: 135.78 (+3.22)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 315.88 (+6.45), AMZN: 524.70 (-6.71), MON: 100.95 (-0.51), COP: 52.49 (+1.84), AMGN: 173.17 (+7.63), XOM: 82.20 (+2.94), SLB: 82.65 (+0.89), CELG: 135.78 (+3.22), RIG: 13.98 (+0.87), GILD: 113.03 (+2.49), DD: 56.03 (-0.70), PX: 114.68 (+2.86), CVX: 92.09 (+2.95), DOW: 46.65 (+1.02), REGN: 557.06 (+17.03)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 315.88 (+6.45), COF: 78.23 (-0.38), GILD: 113.03 (+2.49), FCX: 12.41 (+1.04), RCPT: 227.79 (+0.70), CLF: 2.95 (+0.55), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 113.03 (+2.49), IBB: 382.50 (+8.92), CELG: 135.78 (+3.22)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 36.45 (+0.97), BIIB: 315.88 (+6.45), BBC: 36.90 (+0.72), ADRO: 26.69 (+0.29), KITE: 72.33 (+3.47), NK: 33.89 (+33.89), ALXN: 202.89 (+4.79), RCPT: 227.79 (+0.70), TEVA: 71.16 (-0.84), JUNO: 48.97 (+1.17), CELG: 135.78 (+3.22)
Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better
at The Street - Fri Jul 24, 1:08PM CDT
Jim Cramer answers viewers' questions on Biogen and weighs in on better alternatives. He also responds to questions on Ford and touches into the telecom players.
AMBA: 122.41 (+2.96), AMZN: 524.70 (-6.71), BIIB: 315.88 (+6.45), GPRO: 63.00 (+1.73), F: 14.88 (+0.33), ITEK: 18.02 (+1.26), FB: 94.86 (+0.69), GOOG: 626.34 (-0.92), CELG: 135.78 (+3.22), NFLX: 107.25 (+0.82), AGN: 337.36 (+10.38), T: 34.34 (+0.02), GILD: 113.03 (+2.49), S: 3.30 (+0.20), DTV: 93.55 (+1.36), GM: 31.28 (+0.23), TMUS: 37.00 (+0.50), TWTR: 35.82 (+1.12), VZ: 45.80 (-0.03), REGN: 557.06 (+17.03)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 315.88 (+6.45), VRX: 257.64 (+0.34), LLY: 85.58 (+1.43), ABBV: 70.82 (+1.48), BMY: 64.44 (+0.14), CELG: 135.78 (+3.22)
When Leader Goes Down, Whole Sector Feels It
at The Street - Fri Jul 24, 10:24AM CDT
Biogen's weak numbers leave biotechs ailing.
BIIB: 315.88 (+6.45), COF: 78.23 (-0.38), GILD: 113.03 (+2.49), RCPT: 227.79 (+0.70), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
Stocks Open Mixed And Wild; Maxim, Visa, Amazon Spike
at Investor's Business Daily - Fri Jul 24, 9:39AM CDT
Stocks set out in a tightly-mixed start Friday, with both the Nasdaq and S&P 500 trading about 1% lower so far for the week. The Nasdaq pulled up 0.3%. The Dow Jones industrial average managed a 0.1% gain. The S&P 500 hung out a fractional loss....
AMBA: 122.41 (+2.96), MXIM: 34.67 (+0.82), BIIB: 315.88 (+6.45), AMZN: 524.70 (-6.71), TRIP: 79.95 (-0.65), CELG: 135.78 (+3.22), JNPR: 27.29 (-0.14), CI: 145.66 (-0.24), ANTM: 153.34 (+1.84), V: 74.83 (+0.97), SAVE: 61.23 (+1.45), COF: 78.23 (-0.38), AAL: 41.13 (+0.99)
Celgene Delivers as Expected in Q2, but Raises New Questions
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 24, 9:10AM CDT
Source: Food and Drug Administration via Facebook. Biotech blue-chip stock Celgene (NASDAQ: CELG) knows only one gear when it comes to earnings season: overdrive. With the exception of the fourth-quarter of 2013, Celgene has topped Wall Street's...
CELG: 135.78 (+3.22)
Celgene posts 36% rise in Q2 2015 adjusted net income
M2 - Fri Jul 24, 5:37AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) on Thursday declared its adjusted net income of USD1,019m for the second quarter of 2015 .
CELG: 135.78 (+3.22), CELGZ: 2.03 (+0.03)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 227.79 (+0.70), ABBV: 70.83 (+1.49), CELG: 135.78 (+3.22)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 135.78 (+3.22)
Biotech NantKwest Stock Surges On 1st Day Of Trading
at Investor's Business Daily - 1 hr 46 mins ago
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 72.33 (+3.47), NK: 33.89 (+33.89), ALXN: 202.89 (+4.79), RCPT: 227.79 (+0.70), AMGN: 173.17 (+7.63), JUNO: 48.97 (+1.17), CELG: 135.78 (+3.22)
Celgene (CELG) Crosses Pivot Point Resistance at $133.64
Comtex SmarTrend(R) - Tue Jul 28, 9:35AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $132.37 today and has reached the first level of resistance at $133.64. Investors may be interested in a cross of the next upside pivot targets of $134.71 and $137.05.
CELG: 135.78 (+3.22)
Celgene Corporation Commences Tender Offer for Receptos, Inc.
Business Wire - Tue Jul 28, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
RCPT: 227.79 (+0.70), CELG: 135.78 (+3.22), CELGZ: 2.03 (+0.03)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 315.88 (+6.45), GILD: 113.03 (+2.49), CELG: 135.78 (+3.22)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.73%
Comtex SmarTrend(R) - Mon Jul 27, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 135.78 (+3.22)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.73% Sell Off
Comtex SmarTrend(R) - Mon Jul 27, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $131.11 to a high of $133.45. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $133.95 on volume of 6.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 135.78 (+3.22)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 315.88 (+6.45), GRUB: 32.39 (+1.38), XBI: 259.14 (+7.36), IBB: 382.50 (+8.92), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.34 (-0.15), BIIB: 315.88 (+6.45), LGND: 106.54 (+3.99), AMGN: 173.17 (+7.63), REGN: 557.06 (+17.03), EXEL: 5.54 (+0.10), CELG: 135.78 (+3.22)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 315.88 (+6.45), AMZN: 524.70 (-6.71), MON: 100.95 (-0.51), COP: 52.49 (+1.84), AMGN: 173.17 (+7.63), XOM: 82.20 (+2.94), SLB: 82.65 (+0.89), CELG: 135.78 (+3.22), RIG: 13.98 (+0.87), GILD: 113.03 (+2.49), DD: 56.03 (-0.70), PX: 114.68 (+2.86), CVX: 92.09 (+2.95), DOW: 46.65 (+1.02), REGN: 557.06 (+17.03)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 315.88 (+6.45), COF: 78.23 (-0.38), GILD: 113.03 (+2.49), FCX: 12.41 (+1.04), RCPT: 227.79 (+0.70), CLF: 2.95 (+0.55), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 113.03 (+2.49), IBB: 382.50 (+8.92), CELG: 135.78 (+3.22)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 36.45 (+0.97), BIIB: 315.88 (+6.45), BBC: 36.90 (+0.72), ADRO: 26.69 (+0.29), KITE: 72.33 (+3.47), NK: 33.89 (+33.89), ALXN: 202.89 (+4.79), RCPT: 227.79 (+0.70), TEVA: 71.16 (-0.84), JUNO: 48.97 (+1.17), CELG: 135.78 (+3.22)
Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better
at The Street - Fri Jul 24, 1:08PM CDT
Jim Cramer answers viewers' questions on Biogen and weighs in on better alternatives. He also responds to questions on Ford and touches into the telecom players.
AMBA: 122.41 (+2.96), AMZN: 524.70 (-6.71), BIIB: 315.88 (+6.45), GPRO: 63.00 (+1.73), F: 14.88 (+0.33), ITEK: 18.02 (+1.26), FB: 94.86 (+0.69), GOOG: 626.34 (-0.92), CELG: 135.78 (+3.22), NFLX: 107.25 (+0.82), AGN: 337.36 (+10.38), T: 34.34 (+0.02), GILD: 113.03 (+2.49), S: 3.30 (+0.20), DTV: 93.55 (+1.36), GM: 31.28 (+0.23), TMUS: 37.00 (+0.50), TWTR: 35.82 (+1.12), VZ: 45.80 (-0.03), REGN: 557.06 (+17.03)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 315.88 (+6.45), VRX: 257.64 (+0.34), LLY: 85.58 (+1.43), ABBV: 70.82 (+1.48), BMY: 64.44 (+0.14), CELG: 135.78 (+3.22)
When Leader Goes Down, Whole Sector Feels It
at The Street - Fri Jul 24, 10:24AM CDT
Biogen's weak numbers leave biotechs ailing.
BIIB: 315.88 (+6.45), COF: 78.23 (-0.38), GILD: 113.03 (+2.49), RCPT: 227.79 (+0.70), REGN: 557.06 (+17.03), CELG: 135.78 (+3.22)
Stocks Open Mixed And Wild; Maxim, Visa, Amazon Spike
at Investor's Business Daily - Fri Jul 24, 9:39AM CDT
Stocks set out in a tightly-mixed start Friday, with both the Nasdaq and S&P 500 trading about 1% lower so far for the week. The Nasdaq pulled up 0.3%. The Dow Jones industrial average managed a 0.1% gain. The S&P 500 hung out a fractional loss....
AMBA: 122.41 (+2.96), MXIM: 34.67 (+0.82), BIIB: 315.88 (+6.45), AMZN: 524.70 (-6.71), TRIP: 79.95 (-0.65), CELG: 135.78 (+3.22), JNPR: 27.29 (-0.14), CI: 145.66 (-0.24), ANTM: 153.34 (+1.84), V: 74.83 (+0.97), SAVE: 61.23 (+1.45), COF: 78.23 (-0.38), AAL: 41.13 (+0.99)
Celgene Delivers as Expected in Q2, but Raises New Questions
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 24, 9:10AM CDT
Source: Food and Drug Administration via Facebook. Biotech blue-chip stock Celgene (NASDAQ: CELG) knows only one gear when it comes to earnings season: overdrive. With the exception of the fourth-quarter of 2013, Celgene has topped Wall Street's...
CELG: 135.78 (+3.22)
Celgene posts 36% rise in Q2 2015 adjusted net income
M2 - Fri Jul 24, 5:37AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) on Thursday declared its adjusted net income of USD1,019m for the second quarter of 2015 .
CELG: 135.78 (+3.22), CELGZ: 2.03 (+0.03)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 227.79 (+0.70), ABBV: 70.83 (+1.49), CELG: 135.78 (+3.22)
Celgene (CELG) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Thu Jul 23, 1:11PM CDT
The following Celgene (CELG) conference call took place on July 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
CELG: 135.78 (+3.22)
